These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37556495)

  • 1. Analytical sameness methodology for the evaluation of structural, physicochemical, and biological characteristics of Armlupeg: A pegfilgrastim biosimilar case study.
    Deshmukh A; Goyal R; Sundaram K; Dange K; Lakhote T; Niranjan S; Bharucha J; Mishra A; Vats B; Tiwari S
    PLoS One; 2023; 18(8):e0289745. PubMed ID: 37556495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A demonstration of analytical similarity comparing a proposed biosimilar pegfilgrastim and reference pegfilgrastim.
    Brokx S; Scrocchi L; Shah N; Dowd J
    Biologicals; 2017 Jul; 48():28-38. PubMed ID: 28619479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PF-06881894, a Proposed Biosimilar to Pegfilgrastim, Versus US-Licensed and EU-Approved Pegfilgrastim Reference Products (Neulasta
    Moosavi S; Borema T; Ewesuedo R; Harris S; Levy J; May TB; Summers M; Thomas JS; Zhang J; Yao HM
    Adv Ther; 2020 Jul; 37(7):3370-3391. PubMed ID: 32524499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta
    Wynne C; Schwabe C; Vincent E; Schueler A; Ryding J; Ullmann M; Ghori V; Kanceva R; Stahl M
    Pharmacol Res Perspect; 2020 Apr; 8(2):e00578. PubMed ID: 32333641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural similarity, characterization of Poly Ethylene Glycol linkage and identification of product related variants in biosimilar pegfilgrastim.
    Shekhawat R; Shah CK; Patel A; Srinivasan S; Kapoor P; Patel S; Kumar S; Sonar S; More N; Joshi M; Patel J; Vachhani M; Kodaganti BP; Choavatiya U; Pushpaja A; Argade S; Nuwal N; Kumar M; Khambhampaty S
    PLoS One; 2019; 14(3):e0212622. PubMed ID: 30865643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial.
    Blackwell K; Donskih R; Jones CM; Nixon A; Vidal MJ; Nakov R; Singh P; Schaffar G; Gascón P; Harbeck N
    Oncologist; 2016 Jul; 21(7):789-94. PubMed ID: 27091420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of the totality of evidence supporting the development and approval of a pegfilgrastim biosimilar (LA-EP2006).
    Agarwala SS; Nagl U; Guo X; Bellon A; Heyn J; Dimova-Dobreva M; Shen YM; Schaffar G; Humphrey M; Mathieson N; Koptelova N; Gattu S
    Curr Med Res Opin; 2022 Jun; 38(6):999-1009. PubMed ID: 35392751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin's Ranibizumab with Lucentis
    Singh R; Chauhan R; Saxena A; Shah A; Mondal L; Bakhle D; Shah C; Shah A; Deoghare S; Krishnan N; Godse N
    Indian J Ophthalmol; 2022 Aug; 70(8):3008-3014. PubMed ID: 35918962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.
    Blackwell K; Gascon P; Jones CM; Nixon A; Krendyukov A; Nakov R; Li Y; Harbeck N
    Ann Oncol; 2017 Sep; 28(9):2272-2277. PubMed ID: 28637287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma.
    McBride A; Krendyukov A; Mathieson N; Campbell K; Balu S; Natek M; MacDonald K; Abraham I
    J Med Econ; 2020 Jan; 23(1):28-36. PubMed ID: 31433700
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia.
    McBride A; Campbell K; Bikkina M; MacDonald K; Abraham I; Balu S
    J Med Econ; 2017 Oct; 20(10):1083-1093. PubMed ID: 28722494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective review of the real-world experience of the Pegfilgrastim biosimilar (Lapelga®) to the reference biologic (Neulasta®).
    Wong G; Zhang L; Majeed H; Razvi Y; DeAngelis C; Lam E; McKenzie E; Wang K; Pasetka M
    J Oncol Pharm Pract; 2022 Jan; 28(1):5-16. PubMed ID: 33215563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proposed biosimilar pegfilgrastim shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects.
    Nakov R; Gattu S; Wang J; Velinova M; Schaffar G; Skerjanec A
    Br J Clin Pharmacol; 2018 Dec; 84(12):2790-2801. PubMed ID: 30079636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy.
    Kahan Z; Grecea D; Smakal M; Tjulandin S; Bondarenko I; Perjesi L; Illes A; Horvat-Karajz K; Aradi I
    BMC Cancer; 2019 Feb; 19(1):122. PubMed ID: 30727980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegfilgrastim-jmdb/MYL-1401H: A Pegfilgrastim Biosimilar.
    Hoy SM
    BioDrugs; 2019 Feb; 33(1):117-120. PubMed ID: 30701419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia.
    Aapro M; Cornes P; Abraham I
    J Oncol Pharm Pract; 2012 Jun; 18(2):171-9. PubMed ID: 21610020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim.
    Kang KW; Lee BH; Jeon MJ; Yu ES; Kim DS; Lee SR; Sung HJ; Choi CW; Park Y; Kim BS
    Cancer Med; 2020 Sep; 9(17):6102-6110. PubMed ID: 32633471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RGB-02 (biosimilar pegfilgrastim) in the treatment of chemotherapy-induced neutropenia.
    Sántha D; Illés A; Aradi I; Horvát-Karajz K; Kahán Z
    Future Oncol; 2019 Jun; 15(18):2083-2092. PubMed ID: 31210542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilar Pegfilgrastim-cbqv Demonstrated Similar Immunogenicity to Pegfilgrastim in Healthy Subjects Across Three Randomized Clinical Studies.
    Civoli F; Finck B; Tang H; Hodge J; O'Kelly H; Vexler V
    Adv Ther; 2022 Mar; 39(3):1230-1246. PubMed ID: 35034311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LA-EP2006: A Pegfilgrastim Biosimilar.
    Hoy SM
    BioDrugs; 2019 Apr; 33(2):229-232. PubMed ID: 30887256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.